Coverage For Jardiance 25Mg By UnitedHealthcare
Jardiance 25mg (empagliflozin) is an oral pill taken by type 2 diabetic patients to help control blood sugar levels. It is also used to reduce the risk of heart attack, stroke or heart failure among people suffering from type 2 diabetes. Empagliflozin helps the kidneys to eliminate glucose from the bloodstream, thereby controlling the blood sugar levels. Jardiance 25mg should not be taken by people with type 1 diabetes, severe kidney disease or who are undergoing dialysis. Taking Jardiance 25mg can also result in side effects such as urinary tract infection, anxiety, fast heartbeat, dehydration, dizziness, genital infections, bloody urine, headache, and weakness. Jardiance 25mg is often suggested along with diet and exercise in order for it to be highly effective in controlling blood sugar levels. The commonly recommended dosage for Jardiance is 10mg taken every morning. The dosage can be increased to 25mg for patients who are tolerating Jardiance. Jardiance is approved by the U.S. Food and Drug Administration after its safety and effectiveness were tested in seven clinical trials with over 4500 people suffering from type 2 diabetes. Medicare offers coverage for Jardiance 25mg prescription drugs. Medicare Part D and Medicare Advantage plans cover this drug by 67%.